Tarsus Pharmaceuticals, Inc.

TARSNasdaq· Biological Products, (No Diagnostic Substances)

Price History

Revenue

$451.4M

▲ 146.7% YoY

Net Income

-$66.4M

▲ 42.5% YoY

EPS

$-1.59

▲ 48.2% YoY

Cash

$183.6M

▲ 93.7% YoY

FY 2025 · As of 2025-12-31

Pro

10-K Year-over-Year Diff

AI-powered analysis of what changed between the last two annual reports — new risks, removed language, strategy shifts.